Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Gastroparesis - Overview
Diabetic Gastroparesis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Diabetic Gastroparesis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Gastroparesis - Companies Involved in Therapeutics Development
AlfaSigma SpA
Allergan Plc
Atlantic Healthcare Plc
Bird Rock Bio Inc
Censa Pharmaceuticals Inc
CinRx Pharma LLC
ETX Pharma Inc
Evoke Pharma Inc
Johnson & Johnson
Takeda Pharmaceutical Co Ltd
Vanda Pharmaceuticals Inc
Diabetic Gastroparesis - Drug Profiles
CIN-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNSA-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metoclopramide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nimacimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
renzapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-906 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tradipitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
velusetrag - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diabetic Gastroparesis - Dormant Projects
Diabetic Gastroparesis - Discontinued Products
Diabetic Gastroparesis - Product Development Milestones
Featured News & Press Releases
Jan 21, 2020: FDA accepts Evoke Pharma’s NDA resubmission for Gimoti
Dec 20, 2019: Evoke resubmits Gimoti new drug application to FDA
Sep 17, 2019: Evoke Pharma completes manufacturing of commercial scale registration batches of Gimoti
Aug 08, 2019: Evoke Pharma to resubmit Gimoti NDA based on FDA Meeting minutes and announces second quarter 2019 fincial results
Jun 27, 2019: Evoke Pharma requests Type A FDA meeting to plan for resubmission of Gimoti NDA
May 17, 2019: Allergan expands PLEDGE Clinical Research Program in Diabetic Gastroparesis
Apr 02, 2019: Evoke Pharma receives complete response letter and recommendations to address deficiencies from FDA for Gimoti NDA
Jan 07, 2019: Evoke Pharma signs commercial and fincial agreement for its Lead Product Gimoti in the U.S. with Novos Growth Partners
Dec 03, 2018: Vanda announces positive phase II study results for Tradipitant in patients with gastroparesis
Oct 08, 2018: Allergan to present data on Relamorelin at ACG 2018
Aug 16, 2018: Evoke Pharma’s Gimoti NDA Accepted for FDA Review
Jun 04, 2018: Evoke Announces FDA Submission of New Drug Application for Gimoti
May 15, 2018: EndoLogic Announces FDA Accepts Cardiac Safety Trial for Renzapride in Patients with Gastroparesis
May 10, 2018: Evoke Granted Gender Specific Patent for Gimoti in Mexico
Apr 30, 2018: Evoke Granted First Gender Specific Patent for Gimoti
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Diabetic Gastroparesis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Diabetic Gastroparesis, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Diabetic Gastroparesis - Pipeline by AlfaSigma SpA, H1 2020
Diabetic Gastroparesis - Pipeline by Allergan Plc, H1 2020
Diabetic Gastroparesis - Pipeline by Atlantic Healthcare Plc, H1 2020
Diabetic Gastroparesis - Pipeline by Bird Rock Bio Inc, H1 2020
Diabetic Gastroparesis - Pipeline by Censa Pharmaceuticals Inc, H1 2020
Diabetic Gastroparesis - Pipeline by CinRx Pharma LLC, H1 2020
Diabetic Gastroparesis - Pipeline by ETX Pharma Inc, H1 2020
Diabetic Gastroparesis - Pipeline by Evoke Pharma Inc, H1 2020
Diabetic Gastroparesis - Pipeline by Johnson & Johnson, H1 2020
Diabetic Gastroparesis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Diabetic Gastroparesis - Pipeline by Vanda Pharmaceuticals Inc, H1 2020
Diabetic Gastroparesis - Dormant Projects, H1 2020
Diabetic Gastroparesis - Discontinued Products, H1 2020